ADVR, a bio-pharmaceutical company, recently announced that effective June 27, 2006, the company received US patent approval for treatment of rheumatoid arthritis by administering Product R (AVR118). Product R is a peptide-nucleic acid preparation. It’s combinations of peptides, amino acids, nucleosides, nucleotides and nucleic acid bases modulate the immune system.
According to the company’s website, the drug “appears to stimulate the pro inflammatory response required to combat viral infections, such as HIV; and to dampen aberrant autoimmune-type inflammatory responses, which often occur in diseases such as rheumatoid arthritis.” ADVR believes that in the future, Product R may be used to treat a variety of diseases including several conditions associated with cancer; cachexia, or body wasting, in patients with acquired immune deficiency syndrome (AIDS); human immunodeficiency virus (HIV), including AIDS as a combination therapy; type 2 diabetes; human papilloma virus (HPV); and rheumatoid arthritis.
Published On: August 16, 2006